In this study, a TLR1/TLR2 agonist enhanced the survival and function of administered T cells and altered the glioma microenvironment by simultaneously elevating the number of CD8+ positive T cells and down-regulating the number of immunosuppressive myeloid-derived suppressor cells (MDSCs). Here, TLR2 is linked to central nervous system cancer.